Abu-Freha Naim, Abu Tailakh Muhammad, Fich Alexander, Abu Bader Nasreen, Shemer-Avni Yonat, Alsana Farhan, Gasper Nava, Abu-Kaf Heba, Etzion Ohad
The Institute of Gastroenterology and Hepatology, Soroka University Medical Center, Beer-Sheva 84101, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, Israel.
J Clin Med. 2020 Jun 19;9(6):1922. doi: 10.3390/jcm9061922.
Adherence to treatment of chronic Hepatitis B Virus (HBV) is an important issue and can affect the complication rate. Nucleos(t)ide analogue as oral treatments are used for patients with necro-inflammatory activity and high viral load, with the goal of decline the complication rate such cirrhosis and hepatic cancer. We aimed to investigate the adherence to chronic HBV treatment. Chronic HBV patients with dispensing medication rates (DMR) of at least 80% were defined as high adherence group (HAG) and those who dispensed less than 80% as low adherence group (LAG). The study included 273 patients. 90 patients (33%) were in the LAG and 183 (67%) in the HAG. The All-cause mortality in the LAG was 15.6%, and 8.7% among the HAG (-value = 0.09). 185 patients were of Jewish origin (mean age of 52.96 ±14.6 years, 30% women) and 88 patients of Arab Bedouin (AB) origin (mean age of 40.86 ± 13.96 years (-value < 0.001), 42% women). The proportion of Jewish patients with high adherence was 71% (131 patients) versus 59% (52 patients) in AB patients (-value = 0.054). The all-causes mortality was 14.6% among Jewish origin and 3.4% of AB (-value = 0.01). We conclude that, two third of HBV carriers are with high level adherence to treatment in southern Israel, with lower but marginally significant all-cause mortality. No-significant differences in adherence patterns were noted between Arab Bedouin and Jews.
坚持慢性乙型肝炎病毒（HBV）治疗是一个重要问题，并且会影响并发症发生率。核苷（酸）类似物作为口服治疗药物用于有坏死性炎症活动和高病毒载量的患者，目的是降低诸如肝硬化和肝癌等并发症的发生率。我们旨在调查慢性HBV治疗的依从性。将配药率（DMR）至少为80%的慢性HBV患者定义为高依从性组（HAG），而配药率低于80%的患者定义为低依从性组（LAG）。该研究纳入了273名患者。90名患者（33%）属于LAG，183名（67%）属于HAG。LAG的全因死亡率为15.6%，HAG为8.7%（P值 = 0.09）。185名患者为犹太裔（平均年龄52.96±14.6岁，30%为女性），88名患者为阿拉伯贝都因（AB）裔（平均年龄40.86±13.96岁（P值<0.001），42%为女性）。犹太裔患者中高依从性的比例为71%（131名患者），而AB裔患者中为59%（52名患者）（P值 = 0.054）。犹太裔的全因死亡率为14.6%，AB裔为3.4%（P值 = 0.01）。我们得出结论，在以色列南部，三分之二的HBV携带者对治疗有高水平的依从性，全因死亡率较低但有边缘性显著差异。阿拉伯贝都因人和犹太人在依从模式上未发现显著差异。
